ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS

Projektinformationen

LYMFOXP1

ID Finanzhilfevereinbarung: 328177

Abgeschlossenes Projekt

Startdatum 1 November 2013

Enddatum 8 April 2016

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 230 036,60

EU-Beitrag € 230 036,60

Koordiniert durch

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Spain

Ziel

"FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that has been demonstrated to be expressed in a subset of activated B-cell type (ABC) diffuse B-cell lymphomas (DLBCLs). Strong FOXP1 expression appears to have an additive adverse role in the pathogenesis and clinical behavior of ABC-DLBCL. We believe that a better understanding of the molecular impact of FOXP1 deregulation in DLBCL will help us to improve the correct stratification of cancer patients as a prerequisite for acute diagnosis, and will allow us to propose novel pre-clinical therapeutic strategies to target the FOXP1-axis. To achieve this, we propose to characterize a collection of primary human DLBCL samples, stablished cell lines and the novel Emu-FOXP1 transgenic mouse model that has been recently generated in our lab, in an attempt to identify deregulated B-cell functional pathways, as well as sets of genetic and epigenetic events that might be ""passengers"" and/or ""drivers"" of lymphomagenesis. Our preliminary data has identified the B-cell mutagenic enzyme AID (activation-induced deaminase) as a FOXP1-target gene that could promote genetic and epigenetic instability in germinal-center B-cells. Consequently, we propose to explore the functional interaction of FOXP1 and AID both during normal B-cell activation and malignant B-cell transformation. By exploring functional and therapeutic strategies of targeting potential FOXP1/AID-related targets we pursue the development of translational protocols that could be used in the clinic to better diagnose patients with DLBCL and set the basis for designing future treatments and clinical trials."

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › biochemistry › biomolecules › proteins › enzymes
• natural sciences › biological sciences › genetics › epigenetics

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2012-IIF - Marie Curie Action: "International Incoming Fellowships"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2012-IIF
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IIF - International Incoming Fellowships (IIF)

Koordinator

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Kontakt Verwaltung

Andrew Solomon (Dr.)

• EU-Beitrag: € 230 036,60
• Adresse: AVENIDA DE PIO XII 55 ; 31008 Pamplona ; Spanien
• Region: Noreste › Comunidad Foral de Navarra › Navarra
• Aktivitätstyp: Research Organisations
• Gesamtkosten: Keine Daten